Canalytics' suite of tools analyzes what was once hidden about cannabis products, scientific clarity on their effects for customer matchmaking. We maximize therapeutic and adult-use benefits for informed decision-making across brands, breeders, cultivators, labs, and dispensaries. Backed by over 5,000 studies, Canalytics helps clients maintain and monetize an unmatched competitive advantage with actionable insights.
Industry-Wide Impact: Our Comprehensive Approach
Canalytics empowers all sectors of the cannabis industry—from breeding, phenohunting, and cultivation to sale and customer product matchmaking. We provide innovative solutions that drive the development and accessibility of premium medical and recreational cannabis products. Our cutting-edge analytics and insights optimize every stage of the supply chain, ensuring unparalleled quality, efficiency, and consumer satisfaction. By partnering with Canalytics, businesses can elevate their operations while delivering superior cannabis experiences to their customers.
Therapeutic Effects
Studies Analyzed
5,213
Cannabis Effects Evaluated
30
COAs Analyzed
25,271
Adult Use Effects
Therapeutic Effects Analyzed
Adult Use Effects Analyzed
Scientific Cannabis Formulas
Scientific Cannabis Formulas
Purchase, License, Productize
Canalytics is meticulously researching and developing 50 proprietary cannabis genetic profiles that precisely target 30 adult use and 20 therapeutic effects, which will be available for licensing and sale.
Our Team: Pioneers of Innovative Precision in Cannabis
Meet the gifted minds behind Canalytics—where science meets innovation. Each member of our team brings a wealth of expertise and a relentless drive to revolutionize scientific cannabis advancements across the entire industry. From uncovering therapeutic effects to enhancing product development, our specialists are at the forefront of the industry, ensuring that our solutions are not just advanced but also actionable and accurate.
Co-Founder, Research & CTO
Matthew Widmer
Matthew brings over two decades of extensive research and technological innovation to Canalytics. His multidisciplinary background in neuroscience, cognitive science, and computer science, and comprehensive analysis of 7,000+ studies on the endocannabinoid system and cannabinoid-terpene effect synergy provide a robust scientific foundation for Canalytics’ cutting-edge algorithmic analysis systems.
Matthew brings an impressive track record in designing sophisticated computational systems. In 2007, he spearheaded the development of a Crestron automation system with 5,000+ relays. Throughout his career, Matthew has been at the forefront of advancements ranging from digital therapeutics and VR/AR to innovative health-boosting systems utilizing emotion tracking feedback loops for personalized recommendations.
Scientific Advisor
Dr. Janice MV Knox, MD, MBA
Dr. Janice Vaughn-Knox, MD, MBA is a retired board certified anesthesiologist, endocannabinologist, and certified cannabinoid medicine specialist. Dr. Janice is one of a family of 4 clinicians that believes science, research and technology will disrupt health care as it has been known.
The future of cannabis medicine will depend on how well the physiology of the body is known and the correct clinical application of the pharmacology of cannabis and other botanicals.
Co-Founder & Business Dev
Brent Stevens
Brent Stevens, co-founder of Canalytics, brings 23 years of expertise in the cannabis industry, spanning innovative product development, building labs, cultivation facilities, dispensaries, managing medical grows and founding multiple global brands. Including spearheading the award-winning Flower Mill, now a staple in the industry.
With a background in c-suite company development and sales, Brent also contributes to The Shire Group, streamlining operations and compliance for cannabis businesses. Committed to social responsibility, he supports initiatives providing cannabis to communities in need. Brent’s laser focus on improving cannabis quality and experience across the therapeutic and adult use cannabis has driven advancements shaping the industry.
Scientific Advisor
Dr. Jessica Knox, MD, MBA, MPH
Dr. Jessica Knox is a board-certified preventive medicine physician with 6 years of clinical experience in cannabinoid medicine. Dr. Jessica is a co-founder of several organizations, including co-founder of Doctors Knox, Inc. and Pivital Holdings; and the Association for Cannabis Health Equity and Medicine (ACHEM), the first national medical association for BIPOC professionals seeking to heal themselves and their communities through cannabis education, advocacy, and application.
Scientific Advisor
Dr. Rachel Knox, MD, MBA
Dr. Rachel Knox, MD, MBA is an endocannabinologist specializing in cannabinoid medicine, and a policy expert on cannabis and psychedelic health equity. She’s the creator and president of the Cannabis Health Equity Movement (CHEM)®, comprising the Association for Cannabis Health Equity and Medicine (ACHEM), CHEM Allyance, and CHEM Cooperative; and is co-founder of Doctors Knox, Inc. and Pivital Holdings.
She is the immediate past chair of the Oregon Cannabis Commission, immediate past Vice Chair and Equity Chair of the Oregon Psilocybin Advisory Board, and a founding board member of Cannabis Regulators of Color Coalition (CRCC).
Scientific Advisor
Dr. David Knox, MD
Dr. David Knox is a board certified emergency medicine physician with nearly a decade of clinical experience in cannabinoid medicine. Along with his family, Dr. David founded Doctors Knox, Inc., the American Cannabinoid Clinics, delivering precision cannabinoid medicine to patients; and Pivital Edu, which develops comprehensive training for healthcare professionals in the ECS, endocannabinology and cannabinology.
Doctor Testimonials
Committed to Robust Scientific Innovation
Driven by science and fueled by passion, our team’s collective vision is to empower clients with unparalleled insights into cannabis genetics and effects and establish trust in cannabis where it matters most. At Canalytics, we’re more than just analysts and researchers; we’re your partners in navigating the complex landscape of cannabis with data-driven confidence.